Don't leave, TurboMice™ is coming to you!
Connecting to server... 0%
  • 4-Week Delivery: World’s fastest custom mouse model development.
  • TurboMice™ Tech: Proprietary high-efficiency gene-editing platform.
  • Full Capabilities: Expert conditional knockouts, knock-ins, and humanized models.
  • Validated Quality: Guaranteed high precision and model viability.
Partners' Projects

GJB2 (Cx26) Deafness Mouse Model

Strain Name

GJB2 (Cx26) Deafness Mouse Model

Editing Type

Whole-body knockout; Cre-loxP conditional knockout; inducible conditional knockout; human variant knock-in

Gene Name

Gjb2 (mouse) / GJB2 (human)

Gene Synonyms

Mouse: Cx26; Cxne; Cnx26; Gjb-2
Human: HID; KID; PPK; BAPS; CX26; DFNA3; DFNB1; NSRD1; DFNA3A; DFNB1A

Strain Background

C57BL/6N

NCBI No.

Mouse: Gene ID: 14619 / MGI:95720
Human: Gene ID: 2706 / HGNC:4284 / MIM:121011

1. AAV / base editing / prime editing preclinical validation The conditional knockout plus the homozygous 35delG line is a core efficacy platform for GJB2 gene therapy programs (e.g., Sensorion, Yilai Shu’s group), measuring EP recovery, ABR thresholds, and gap junction plaque restoration.

2. Cell-specific promoter and safety evaluation Cross with tdTomato reporter lines to confirm vectors transduce supporting cells only and leave hair cells untouched — the auditory toxicity hurdle that GJB2 therapies must clear.

3. Neuroprotection combined with cochlear implantation Late-induced models keep spiral ganglion neurons alive for roughly two months, enabling testing of whether electrical stimulation plus BDNF or similar approaches preserve neurons and improve implant outcomes.

4. Small-molecule and combination screening On human variant backgrounds, screen ion-homeostasis modulators, PARP inhibitors, and calcium channel blockers — an alternative route for patients unsuited to gene therapy, such as those with extensive hair cell loss.

The GJB2 (Cx26) Deafness Mouse Model carries variants in the Gjb2 gene encoding connexin 26, reproducing hereditary non-syndromic hearing loss of the DFNB1 type. Cx26 is a gap junction protein responsible for potassium recycling in supporting cells of the inner ear; it is also indispensable during placental development in mice, where glucose and other nutrients are transported between mother and fetus through Cx26 channels. Whole-body knockout is therefore embryonic lethal: homozygous loss of function impairs placental nutrient transport and the embryo dies in mid-gestation. Conventional GJB2 models use Cre-loxP to delete the gene in specific cell types or at specific developmental stages. TurboMice™, VeloGene’s in-house high-efficiency tetraploid complementation platform, resolves this differently: tetraploid embryos develop exclusively into placental (extraembryonic) tissue, so diploid embryonic stem cells carrying homozygous deafness mutations can complete fetal development without depending on their own GJB2 function — bypassing the in utero death caused by impaired maternal–fetal nutrient transport. TurboMice™ also skips breeding and screening, delivering homozygous GJB2 deafness mice in large batches in as little as two months.

The model supports whole-body homozygous knockout generated directly by TurboMice™, conditional knockout via Cre-loxP, inducible conditional knockout, and homozygous knock-in of human disease variants. Additional variants, alternative genetic backgrounds, and crosses with existing disease models can be customized on request.

1. A complete and clean pathological cascade. Cx26 is expressed only in supporting cells and lateral wall fibrocytes; hair cells themselves are unaffected. After knockout, the sequence runs from endocochlear potential collapse (approximately 100 mV to 40 mV) through secondary hair cell death to neuronal degeneration.

2. A precisely tunable intervention window. Inducible conditional knockout changes phenotype by shifting the dosing time point alone: the same background yields either congenital profound deafness or delayed progressive hearing loss, with tightly controlled variables. It is one of the few deafness models capable of intervention-window studies.

3. Patient-relevant variants. 35delG, 235delC, V37I, and R75W can be knocked in as homozygous lines.

4. Gene therapy plus neuroprotection in one animal. Both the primary mechanism (gene replacement or editing) and the downstream execution of cell death (PARP-1/AIF, calcium overload pathways) can be validated in this model, making it a natural fit for evaluating combined gene therapy and neuroprotection strategies.

FAQ

Game-changing benefits?

While competitors highlight germline efficiency gains, shorter timelines and enhanced 3Rs animal welfare benefits for their technologies, these are merely incremental improvements over traditional approaches. In sharp contrast, our proprietary technology delivers fully pure, homogeneous lineages—every single cell of the mice is derived exclusively from totipotent ES cells, with guaranteed 100% germline transmission efficiency. To experience these unparalleled benefits firsthand, enquire about your custom mouse model project with us or order embryos for in-house validation at your facility.

•Free initial design proposal with zero obligations.​
•Request a free quote!

All model generation projects of Mingceler operate under a fee-for-service framework.
IP Ownership: All intellectual property rights related to custom mouse models, including derived organs, tissues, cells, and biological materials, are the sole and exclusive property of the Client.
Third-Party Transfer Permission: The Client may independently decide to retain, utilize, or commercialize their custom models project materials (e.g., targeting vectors, ES cells, mouse lines) without the need for prior consent from Mingceler.
Licensing Exemption: The Client has full autonomy over all uses of the custom models or their derivatives, including but not limited to commercialization, distribution to third parties, and publication involving model data. No written license from Mingceler is required for such uses.

This website uses cookies

We use cookies to personalize content, provide social media features, and analyze our traffic. We also share information about your use of our site with our analytics partners. You can change your preferences at any time. For more information, please see our Privacy Policy Cookie Policy